鼻窦未分化癌的现代治疗方法和疗效:一项荟萃分析。

IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY
Manuela Burggraf MD, Stefan Schiele PhD, Rubens Thölken MD, Francisco José Farfán López MD, Noran Elawany, Johannes Zenk PhD, Johannes Doescher PhD
{"title":"鼻窦未分化癌的现代治疗方法和疗效:一项荟萃分析。","authors":"Manuela Burggraf MD,&nbsp;Stefan Schiele PhD,&nbsp;Rubens Thölken MD,&nbsp;Francisco José Farfán López MD,&nbsp;Noran Elawany,&nbsp;Johannes Zenk PhD,&nbsp;Johannes Doescher PhD","doi":"10.1002/hed.27910","DOIUrl":null,"url":null,"abstract":"<p>Induction chemotherapy (IC) recently gained importance for treatment of sinonasal undifferentiated carcinoma (SNUC). We analyzed our SNUC cases and performed a meta-analysis with focus on survival-rates stratified by treatment. SNUC cases at our institution were retrospectively evaluated. A systematic literature review was conducted to analyze treatment and outcome of SNUC. To calculate 5-year and 2-year overall survival (OS), individual patient data (IPD) were analyzed using Kaplan–Meier estimators and Cox proportional hazard regression to identify associations between types of therapy and survival. A random effects model for pooled estimates of 5-year survival was applied to studies without IPD data. Five-year OS of our SNUC cases (<i>n</i> = 9) was 44.4%. The IPD analysis (<i>n</i> = 192) showed a significantly better 5-year OS for patients who received induction chemotherapy (72.6% vs. 44.5%). The pooled 5-year OS of 13 studies identified in the literature search was 43.8%. IC should be considered in every patient diagnosed with SNUC.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hed.27910","citationCount":"0","resultStr":"{\"title\":\"Contemporary treatment and outcome of sinonasal undifferentiated carcinoma: A meta-analysis\",\"authors\":\"Manuela Burggraf MD,&nbsp;Stefan Schiele PhD,&nbsp;Rubens Thölken MD,&nbsp;Francisco José Farfán López MD,&nbsp;Noran Elawany,&nbsp;Johannes Zenk PhD,&nbsp;Johannes Doescher PhD\",\"doi\":\"10.1002/hed.27910\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Induction chemotherapy (IC) recently gained importance for treatment of sinonasal undifferentiated carcinoma (SNUC). We analyzed our SNUC cases and performed a meta-analysis with focus on survival-rates stratified by treatment. SNUC cases at our institution were retrospectively evaluated. A systematic literature review was conducted to analyze treatment and outcome of SNUC. To calculate 5-year and 2-year overall survival (OS), individual patient data (IPD) were analyzed using Kaplan–Meier estimators and Cox proportional hazard regression to identify associations between types of therapy and survival. A random effects model for pooled estimates of 5-year survival was applied to studies without IPD data. Five-year OS of our SNUC cases (<i>n</i> = 9) was 44.4%. The IPD analysis (<i>n</i> = 192) showed a significantly better 5-year OS for patients who received induction chemotherapy (72.6% vs. 44.5%). The pooled 5-year OS of 13 studies identified in the literature search was 43.8%. IC should be considered in every patient diagnosed with SNUC.</p>\",\"PeriodicalId\":55072,\"journal\":{\"name\":\"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hed.27910\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hed.27910\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hed.27910","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

最近,诱导化疗(IC)在鼻窦鼻腔未分化癌(SNUC)的治疗中变得越来越重要。我们分析了本院的鼻窦未分化癌病例,并进行了一项荟萃分析,重点关注按治疗方法分层的生存率。我们对本机构的鼻窦未分化癌病例进行了回顾性评估。我们进行了系统的文献回顾,分析了SNUC的治疗和结果。为了计算5年和2年总生存率(OS),我们使用卡普兰-梅耶估计器和Cox比例危险回归分析了单个患者数据(IPD),以确定治疗类型与生存率之间的关联。对于没有IPD数据的研究,则采用随机效应模型对5年生存率进行汇总估计。我们的SNUC病例(n = 9)的5年OS为44.4%。IPD分析(n = 192)显示,接受诱导化疗的患者的5年生存率明显更高(72.6%对44.5%)。文献检索中发现的13项研究的5年生存率合计为43.8%。每一位确诊为SNUC的患者都应考虑接受IC治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Contemporary treatment and outcome of sinonasal undifferentiated carcinoma: A meta-analysis

Contemporary treatment and outcome of sinonasal undifferentiated carcinoma: A meta-analysis

Induction chemotherapy (IC) recently gained importance for treatment of sinonasal undifferentiated carcinoma (SNUC). We analyzed our SNUC cases and performed a meta-analysis with focus on survival-rates stratified by treatment. SNUC cases at our institution were retrospectively evaluated. A systematic literature review was conducted to analyze treatment and outcome of SNUC. To calculate 5-year and 2-year overall survival (OS), individual patient data (IPD) were analyzed using Kaplan–Meier estimators and Cox proportional hazard regression to identify associations between types of therapy and survival. A random effects model for pooled estimates of 5-year survival was applied to studies without IPD data. Five-year OS of our SNUC cases (n = 9) was 44.4%. The IPD analysis (n = 192) showed a significantly better 5-year OS for patients who received induction chemotherapy (72.6% vs. 44.5%). The pooled 5-year OS of 13 studies identified in the literature search was 43.8%. IC should be considered in every patient diagnosed with SNUC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.00
自引率
6.90%
发文量
278
审稿时长
1.6 months
期刊介绍: Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信